DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note released on Friday morning. The brokerage issued a hold rating on the stock.

Several other research firms have also issued reports on DBVT. HC Wainwright increased their price objective on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and set a $10.00 target price on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Trading Down 5.5 %

DBVT stock opened at $4.47 on Friday. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $9.49. The business’s 50 day moving average is $3.43 and its 200-day moving average is $3.84. The firm has a market cap of $91.95 million, a P/E ratio of -0.99 and a beta of 0.64.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.